Martin Shkreli, the entrepreneur famous for hiking the price of a life-saving medicine and defrauding hedge fund investors, was sentenced Friday to serve 7 years in prison.
Convicted in August on securities fraud charges, Shkreli was a sneering, smirking presence in interviews, Capitol Hill hearings and on the internet—at least until the judge tired of his antics and threw him in jail to await sentencing.
At Friday's hearing, the Wall Street Journal's Rebecca D. O'Brien wrote that Shkreli's own defense lawyer said "There are times I want to hug him...There are times when I want to punch him in the face."
Added Ben Brafman, the lawyer: "Quite frankly, I've got my begging voice on."
It was all to no avail, even after Shkreli wept and promised that he was a changed man. Judge Kiyo Matsumoto said the lengthy sentence had nothing to do with Shkreli's reputation or price-gouging. He faced up to 20 years in prison.
Now 34, Shkreli became well-known after raising the price of Daraprim, a pill used by HIV patients, from from $13.50 to $750. He was arrested on securities fraud charges over an unrelated hedge fund swizz: the prosecution contended he pilfered funds to start another company, while his defense noted he made good on the investments in the long run.
He was banned from Twitter after harassing a woman journalist there; he also fell into the habit of buying internet domains that include the names of journalists who wrote about him, including me. Read the rest
Hospital chain Intermountain Healthcare is leading a industry consortium representing 450 hospitals in total in an initiative to manufacture their own generic drugs, either directly or through subcontractors.
Read the rest
Before being convicted of felony securities fraud, smirking cartoon villain pharma-douche-bro Martin Shkreli had to be tried in front of a jury and this presented a unique problem because everyone hates Martin Shkreli, and thus more than 100 jurors were dismissed from the pool during pre-trial questioning. Here are some of the statements that led to those dismissals. Read the rest
Former pharmaceutical executive Martin Shkreli became famous for hitting AIDS patients with a price hike in a life-saving drug—and then for the fraud charges for which he awaits his day in court. But he's also a bit of an odd duck, eating shit on campus and getting kicked off Twitter for harassment. Now he's been noticed snapping up web domains that include critics' and enemies' names.
Maxwell Tani at Business Insider:
Over the past five months, Shkreli has purchased domains associated with writers from Vice, Vanity Fair, AOL, Bloomberg, Dealbreaker, and Gizmodo, along with others associated with other individuals critical of Shkreli on social media.
Shkreli didn't appear to be too happy when Noisey reporter Phil Witmer published a story ... "Can I buy philwitmer.com right now? Yes I can, and yes I will," he said to whoever was watching his livestream. ...
In the weeks after Shkreli's Twitter account was suspended in January for harassing Teen Vogue writer Lauren Duca, the former exec started buying up domain names for journalists, snagging "marrymelauren.com" on the day he was suspended.
Martin Shkreli keeps buying up the personal domain names of journalists who write about him [BI] Read the rest
The smirking, villainous pharma-hedge-douche-bro Martin Shkreli (previously) bought the rights to the anti-parasitic drug Daraprim -- used to treat malaria, a disease that disproportionately affects the poorest people in the world -- and jacked the price from $13.50/dose to $750/dose. Read the rest
Meme factory/Anonymous birthplace/alt-right breeding ground 4chan is facing challenges similar to those plaguing all ad-supported sites, but as with all things channish, 4chan's problems have their own unique and grotesque wrinkles. Read the rest
William J. Hager of Port St. Lucie, Florida is a 86 year old man who confessed to shooting his 76 year old wife, Carolyn Hager, in her sleep, because the couple could no longer afford her medications, leaving her in pain and wanting to die. Read the rest